GALSTONE DESEASE — A RISK FACTOR SPECIFIC TYPE OF DIABETES

Authors

  • Tereshchenko I. V. Acad. E. A. Wagner Perm State Medical University, Ministry of Health of Russia
  • Kayushev P. E. Acad. E. A. Wagner Perm State Medical University, Ministry of Health of Russia

DOI:

https://doi.org/10.21856/j-PEP.2015.3.08

Keywords:

hormones gastrointestinal tract, incretins, diabetes, ghrelin, metabolic syndrome, C-peptide, gallstone disease.

Abstract

It was analyzed gallstone disease (GSD) as a risk factor for specific form diabetes, to study features of the pathogenesis and course of this form of diabetes, to outline the principles of treatment of disorders of carbohydrate metabolism and diabetes in patients with cholelithiasis. Carbohydrate metabolism was evaluated in 111 patients of cholelithiasis; comparison group 23 people with metabolic syndrome (MS). In patients with MS was found hyperC-peptidemiya. In patients with cholelithiasis levels of C-peptid were normal with a tendency to lower limit of normal, especially when patients were not surgical treated calculous cholecystitis many years. Hyperinsulinism and insulin resistance in the GSD is not found. Gallstone disease patients are at risk for a specific form of diabetes. The pathogenesis of specific form of diabetes is a violation of secretion of incretins gastrointestinal tract. Clinically this form of diabetes resembles type 2 diabetes, but it is fundamentally different of type 2 diabetes by the absence of insulin resistance and hyperinsulinism. The use of GPP-1 and the iDPP-4 is the most suitable method for treating diabetes in the gallstone disease.

References

Vahrushev JaM, Mihajlova OD, Bulychjov VF, Zelenin VA. Gastrojenterologija 2006; 1-2:23.

Ivashkin VT. Gastrojenterologija: Klinicheskie rekomendacii, Moskva, 2009.

Gubergric NB, Lukashevich GM, Golubova OA, et al. Ros Zhurn Gastrojenterologii, Gepatologii, Koloproktologii 2007; 6:11-16.

Dedov II, Shestakova MV. Algoritmy specializirovannoj medicinskoj pomoshhi bol’nym saharnym diabetom, Moskva, 2013.

Dedov II, Shestakova MV. Inkretiny: novaja veha v lechenii saharnogo diabeta 2-go tipa. Prakticheskoe rukovodstvo dlja vrachej, Moskva, 2010.

Kozlova IV, Graushkina EV. Ros Zhurn Gastrojenterologii, Gepatologii, Koloproktologii 2010; 20(3):37-45.

Tihonova TM. Prakt Medicina 2015; 1(86):101-106.

Aleryani S, Huorka M, Payer JJr, et al. Vnitr Lek 1997; 43(11):733-737.

Arora S. Neuropeptydes 2006; 40(6):375-401.

Egido EM, Rodriguez-Gallardo J, Silvestre RA, et al. Eur J Endocrinol 2002; 146 (2):241-244.

Fontana G, Vezzadini P, Azzaroli P. J Clin Med 1969; 50(3):245-259.

Gulubov MV, Hadjipetkov P, Sivrev D, Ilieva G. Hepatogastroenterology 2012; 59(113):26-30.

Kim C, Kim K, Lee H, et al. Pancreas 1999; 18(4):410-414.

Mendes-Sanches N, Ponciano- Rodrigues G, Bermegjo-Martines L, et al. World J Gastroenterol 2006; 12(19):3096-3100.

Reshetnyak VI. World J Hepatol 2012; 4(2):18-34.

Downloads

Published

2021-08-17

How to Cite

Tereshchenko, I. V. ., & Kayushev, P. E. . (2021). GALSTONE DESEASE — A RISK FACTOR SPECIFIC TYPE OF DIABETES. Problems of Endocrine Pathology, 53(3), 59-66. https://doi.org/10.21856/j-PEP.2015.3.08

Issue

Section

CLINICAL ENDOCRINOLOGY